Results 271 to 280 of about 452,734 (338)

Temporal Trends and Short‐ and Long‐Term Mortality of People With Acute Myocardial Infarction and Rheumatoid Arthritis: A Nationwide Cohort Study

Arthritis Care &Research, EarlyView.
Objective We investigated whether a diagnosis of rheumatoid arthritis (RA) affects the quality of inpatient acute myocardial infarction (AMI) care and long‐term mortality post‐AMI. Methods We analyzed data from 784,091 adults, 6,047 with a diagnosis of RA, from England and Wales hospitalized with AMI between 2005 and 2019 from the Myocardial Ischaemia ...
Megan Butler, Nicholas Weight, Muhammad Rashid, Rodrigo Bagur, Purvi Parwani, Samantha Hider, Edward Roddy, Robert Butler, Mamas A. Mamas   +8 more
wiley   +1 more source

Mycophenolate Mofetil Treatment Reduces the Risk of Treatment Escalation Due to Vascular Complications in Limited Cutaneous Systemic Sclerosis: Emulation of a Target Trial From the Italian Rheumatology Society SPRING Registry

Arthritis Care &Research, EarlyView.
Objective Mycophenolate mofetil (MMF) use in limited cutaneous systemic sclerosis (lcSSc) is relatively uncommon because of the lower fibrotic burden and the predominance of vascular complications. In vitro observations and clinical data from transplanted patients suggest a protective effect of MMF on endothelial function.
Enrico De Lorenzis, Gerlando Natalello, Rossella De Angelis, Lucrezia Verardi, Dilia Giuggioli, Gianluigi Bajocchi, Lorenzo Dagna, Silvia Bellando‐Randone, Giovanni Zanframundo, Rosario Foti, Fabio Cacciapaglia, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Valeria Riccieri, Elisabetta Zanatta, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Giuseppe Murdaca, Giuseppina Abignano, Giorgio Pettiti, Alessandra Della Rossa, Maurizio Caminiti, Annamaria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Maria Ilenia De Andres, Alessandro Giollo, Cosimo Bruni, Martina Orlandi, Marco Fornaro, Marta Saracco, Cecilia Agnes, Pier Giacomo Cerasuolo, Gabriella Alonzi, Edoardo Cipolletta, Federica Lumetti, Amelia Spinella, Luca Magnani, Corrado Campochiaro, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria‐Grazia Lazzaroni, Franco Franceschini, Elena Generali, Gianna Mennillo, Simone Barsotti, Giuseppa Pagano Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D'Angelo, Franco Cozzi, Fabrizio Conti, Serena Guiducci, Andrea Doria, Carlo Salvarani, Florenzo Iannone, Maria Antonietta D'Agostino, Clodoveo Ferri, Marco Matucci Cerinic, Silvia Laura Bosello, on behalf of the SPRING Italian Registry Collaborators   +77 more
wiley   +1 more source

Evaluating experimental, knowledge-based and computational cocrystal screening methods to advance drug-drug cocrystal fixed-dose combination development

Alice Parkes, Ahmad Ziaee, Emmet O’Reilly   +2 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nanoformulation and Fixed Dose Combination

International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN)
Nanoformulation refers to the design of drug delivery systems at the nanoscale to enhance solubility, stability, and bioavailability. According to the U.S.
Ram Garg, G. Masih, Bikash Medhi
semanticscholar   +2 more sources

Fixed-Dose Combination (Polypill) for Cardiovascular Disease Prevention: A Meta-Analysis.

American Journal of Preventive Medicine, 2022
INTRODUCTION This meta-analysis was performed to assess the efficacy of fixed-dose combination (polypill) in reducing the risk of mortality and cardiovascular events.
A. Abushouk, A. Sayed, M. Munir, E. Ghanem, O. Abdelfattah, E. Michos, Amgad Mentias, S. Kapadia, S. Nissen   +8 more
semanticscholar   +1 more source

Fabrication of a Shell-Core Fixed-Dose Combination Tablet Using Fused Deposition Modeling 3D Printing.

European journal of pharmaceutics and biopharmaceutics, 2022
Fixed-dose combinations (FDCs) achieve optimal goals for treatment with minimal side effects, decreased administration of large number of tablets, thus, greater convenience, and improved patient compliance.
Abdullah Alzahrani, Sagar Narala, Ahmed Adel Ali Youssef, Dinesh Nyavanandi, S. Bandari, Preethi Mandati, Ahmed Almotairy, Mashan Almutairi, M. Repka   +8 more
semanticscholar   +1 more source

Preparation and In vitro characterization of a novel self-nano emulsifying drug delivery system for a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide

Journal of Drug Delivery Science and Technology, 2021
A fixed-dose combination of Candesartan cilexetil (CAN) and Hydrochlorothiazide (HCTZ) is commonly used for the management of hypertension. CAN (BCS class II) and HCTZ (BCS class IV) suffer from inadequate oral bioavailability.
Moataz B. Zewail, S. El-Gizawy, M. Osman, Yusuf A. Haggag   +3 more
semanticscholar   +1 more source

Optimization of bilayer tablet manufacturing process for fixed dose combination of sustained release high-dose drug and immediate release low-dose drug based on Quality by Design (QbD).

International journal of pharmaceutics, 2021
A fixed dose combination (FDC) bilayer tablet, consisting of high-dose metformin HCl in a sustained release layer and low-dose evogliptin tartrate in an immediate release layer, was developed based on a quality by design (QbD) approach.
Dong Han Won, Heejun Park, Eun-Sol Ha, Hwan-Ho Kim, Sun Woo Jang, Min‐Soo Kim   +5 more
semanticscholar   +1 more source

Fixed-Dose??Combination Lercanidipine/Enalapril

Drugs, 2007
Lercanidipine, a dihydropyridine calcium channel blocker, and enalapril, an ACE inhibitor, are established antihypertensive agents. A fixed-dose tablet formulation of lercanidipine/enalapril is approved in Germany for the treatment of hypertension in patients not responding to monotherapy.
Philip I, Hair, Lesley J, Scott, Caroline M, Perry   +2 more
  +5 more sources

Inhaled fixed-dose combination powders for the treatment of respiratory infections

Expert Opinion on Drug Delivery, 2021
Introduction Respiratory infections are a major cause of morbidity and mortality. As an alternative to systemic drug administration, inhaled drug delivery can produce high drug concentrations in the lung tissue to overcome resistant bacteria.
A. Brunaugh, Shivam Sharma, H. Smyth
semanticscholar   +1 more source